Hematology/Oncology

Top Story

Lenalidomide maintenance extends PFS in elderly patients with diffuse large B-cell lymphoma

May 25, 2017

Lenalidomide maintenance prolonged PFS among elderly patients with diffuse large B-cell lymphoma who had achieved partial or complete response to standard therapy, according to results of the phase 3 REMARC trial.

However, OS rates appeared similar between the two groups.

FDA News

FDA advisory committee supports biosimilar for anemia

May 25, 2017
An FDA advisory panel today supported approval of a biosimilar version of Amgen’s epoetin alfa for the treatment of anemia from various causes. The Oncologic Drugs…
In the Journals Plus

Risk-adapted therapeutic strategies effective for early-stage Hodgkin lymphoma

May 25, 2017
A risk-adapted strategy that intensifies combined-modality treatment in early-unfavorable Hodgkin lymphoma and reduces dosage for early-favorable Hodgkin lymphoma has…
In the Journals

Espresso, cappuccino lower prostate cancer risk

May 25, 2017
Drinking 3 or more cups of Italian-style coffee, such as caffé espresso and moka, as well as their combinations with milk, including caffé latte…
In the Journals Plus

Screen-detected breast cancers persist without treatment

May 25, 2017
Screen-detected breast cancers that went untreated remained visible and suspicious for malignancy at next
More News Headlines »
CME

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

This activity is supported by an educational grant from Novartis.

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and…
More »
Video
Meeting News

VIDEO: Managing immune-related adverse events requires multidisciplinary approach

April 13, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CNE CME

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

This activity is supported by an educational grant from Bristol-Myers Squibb.

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement